NO20014105L - Texanderivater for målrettet cancerterapi - Google Patents

Texanderivater for målrettet cancerterapi

Info

Publication number
NO20014105L
NO20014105L NO20014105A NO20014105A NO20014105L NO 20014105 L NO20014105 L NO 20014105L NO 20014105 A NO20014105 A NO 20014105A NO 20014105 A NO20014105 A NO 20014105A NO 20014105 L NO20014105 L NO 20014105L
Authority
NO
Norway
Prior art keywords
texan
derivatives
cancer therapy
targeted cancer
targeted
Prior art date
Application number
NO20014105A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014105D0 (no
Inventor
Ahmad Safavy
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of NO20014105D0 publication Critical patent/NO20014105D0/no
Publication of NO20014105L publication Critical patent/NO20014105L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20014105A 1999-02-24 2001-08-23 Texanderivater for målrettet cancerterapi NO20014105L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12164299P 1999-02-24 1999-02-24
PCT/US2000/004551 WO2000050059A1 (en) 1999-02-24 2000-02-23 Taxane derivatives for targeted therapy of cancer

Publications (2)

Publication Number Publication Date
NO20014105D0 NO20014105D0 (no) 2001-08-23
NO20014105L true NO20014105L (no) 2001-10-11

Family

ID=22397942

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014105A NO20014105L (no) 1999-02-24 2001-08-23 Texanderivater for målrettet cancerterapi

Country Status (8)

Country Link
US (1) US6191290B1 (de)
EP (1) EP1154782A4 (de)
JP (1) JP4808846B2 (de)
AU (1) AU768027B2 (de)
CA (1) CA2362937C (de)
MX (1) MXPA01008699A (de)
NO (1) NO20014105L (de)
WO (1) WO2000050059A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE505202T1 (de) * 1996-02-08 2011-04-15 Cancer Advances Inc Immunologische methoden zur behandlung von gastrointestinalem krebs
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
CA2287872C (en) * 1997-05-12 2010-07-27 Aphton Corporation Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
CA2328501A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Prevention and treatment of hypergastrinemia
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
EP1383492A4 (de) * 2001-03-23 2008-12-24 Napro Biotherapeutics Inc Molekulare konjugate zur verwendung in der krebstherapie
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002326356A1 (en) * 2001-07-09 2003-01-29 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
WO2003035011A2 (en) * 2001-10-26 2003-05-01 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US20080025981A1 (en) * 2002-03-04 2008-01-31 Young Paul E Cancer-linked genes as targets for chemotherapy
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
KR20050032110A (ko) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 신규의 효능을 갖는 탁산을 포함하는 세포독성제 및 그치료용도
US7981928B2 (en) 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
CN1747747B (zh) * 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
US8420050B2 (en) 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7611692B2 (en) 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20060239923A1 (en) * 2003-01-13 2006-10-26 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
CA2523197C (en) * 2003-04-22 2016-05-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide vectors
EP1794586B1 (de) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoklonale antikörper gegen progastrin
WO2006060664A2 (en) * 2004-12-03 2006-06-08 The Uab Research Foundation Single-drug multi-ligand conjugates for targeted drug delivery
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
CN101160403B (zh) * 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
JP5436856B2 (ja) * 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009012109A2 (en) 2007-07-13 2009-01-22 Emory University Cyanine-containing compounds for cancer imaging and treatment
RU2518240C2 (ru) * 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
CN102099059B (zh) * 2008-06-13 2015-09-23 西塞医疗中心 用于癌症靶向治疗的小分子配体-药物轭合物
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
JP5922104B2 (ja) 2010-05-27 2016-05-24 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｓａｌｕｂｒｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ デューアル機能性の抱合体の化学合成及び抗腫瘍及び抗腫瘍転移作用
MX337464B (es) 2011-06-06 2016-03-07 Arbor Therapeutics Llc Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer.
NZ700073A (en) 2012-04-04 2016-08-26 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
KR102772810B1 (ko) 2017-06-15 2025-02-28 캔서 어드밴시스 아이엔씨 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
CN109999202B (zh) * 2019-01-18 2022-03-22 南阳师范学院 一种介导紫杉醇递送的多功能肽及其应用
WO2022266135A1 (en) 2021-06-16 2022-12-22 Veiled Therapeutics Llc Acid-labile chemotherapeutic paclitaxel based compounds for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
JPH11507535A (ja) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
AU739028B2 (en) * 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998019705A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
WO1999025729A1 (fr) * 1997-11-18 1999-05-27 Chugai Seiyaku Kabushiki Kaisha Composes possedant une activite antitumorale
ES2276708T3 (es) * 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
WO2001074399A1 (en) * 2000-03-30 2001-10-11 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Also Published As

Publication number Publication date
NO20014105D0 (no) 2001-08-23
EP1154782A1 (de) 2001-11-21
JP2002537347A (ja) 2002-11-05
US6191290B1 (en) 2001-02-20
CA2362937A1 (en) 2000-08-31
EP1154782A4 (de) 2002-09-25
MXPA01008699A (es) 2002-06-21
AU768027B2 (en) 2003-11-27
AU3499600A (en) 2000-09-14
JP4808846B2 (ja) 2011-11-02
WO2000050059A1 (en) 2000-08-31
CA2362937C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
NO20014105D0 (no) Texanderivater for malrettet kreftterapi
NO20021400D0 (no) Terapeutiske konazolinderivater
LTPA2020503I1 (lt) Rapamicino darinys, skirtas kasos vėžio gydymui
DE60009147D1 (de) Admantan derivate
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
DK1637127T3 (da) Terapeutisk mikroskum
IS5760A (is) Meðferðarlegar bíarýl afleiður
DE60010448D1 (de) Amid-derivate
IS7670A (is) Samsett meðferð fyrir offjölgunar sjúkdóma
ATE273962T1 (de) 5-phenyl-pyrimidine derivate
PT1235558E (pt) Agentes terapeuticos
NO20024775L (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamid derivater til behandling avsmerte
DE60019864D1 (de) Lasertherapiegerät
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
NO20006047L (no) Fremgangsmåte for genterapi
DK1165071T3 (da) Forbedret cancerbehandling med temozolomid
NO20023971D0 (no) Hormonterapi ved brystcancer
NO20014660L (no) Ledekile-Fòringsrörfresesystem
NO20021976L (no) Selektiv leverterapi
NO20020951D0 (no) Fremgangsmåte for multimodul kryptering
DE50013977D1 (de) Strahlungsleiteinrichtung
FIU990263U0 (fi) Rapuneula
ITCZ990004A0 (it) Apparecchio per auricolo terapia
AUPR773101A0 (en) Multiple targeted radionuclide therapy for cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application